No­var­tis builds block­buster case for En­tresto, beat­ing out a cheap ACE in­hibitor — or not

No­var­tis ex­ecs got the pos­i­tive da­ta they were look­ing for from their PI­O­NEER-HF study of En­tresto to back ac­cel­er­at­ing sales of the heart med­ica­tion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.